Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 367-377 , September 2010

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

  • Lon S. Schneider

      Affiliations

    • Departments of Psychiatry and Neurology, Keck School of Medicine, and Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA
    • Corresponding Author InformationCorresponding author. Tel.: 323-442-7600; Fax: 323-442-7601.
    • ,
  • Richard E. Kennedy

      Affiliations

    • School of Public Health, University of Alabama, Birmingham, AL, USA
    • ,
  • Gary R. Cutter

      Affiliations

    • School of Public Health, University of Alabama, Birmingham, AL, USA
    • ,
  • Alzheimer’s Disease Neuroimaging Initiative

References 

  1. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–413
  2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–746
  3. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–128
  4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–144
  5. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201–209
  6. A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer’s Disease. Available at: http://clinicaltrials.gov/ct2/show/NCT00890890?term=Alzheimer&lead=Bristol&rank=2. Accessed April 15, 2010.
  7. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimer Dement. 2005;1:55–66
  8. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  9. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009;72:1555–1561
  10. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–2414
  11. Wechsler DA. Wechsler Memory Scale—Revised. New York, NY: Psychological Corporation; 1987;
  12. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S13–S21
  13. Folstein MF, Folstein SE, McHugh PR. Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  14. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323–329
  15. Burton A, Altman DG, Royston P, Holder RL. The design of simulation studies in medical statistics. Stat Med. 2006;25:4279–4292
  16. Cohen J. Statistical power analysis. Curr Dir Psychol Sci. 1992;1:98–101
  17. Siddiqui O, Hung H, O’Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009;19:227–246
  18. R Development Core Team (2009). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: http://www.Rproject.org.
  19. Pinheiro JC, Bates DM. Mixed Effects Models in S and S-Plus. New York, NY: Springer; 2000;
  20. Schneider LS, Insel P, Weiner M. Cholinesterase inhibitors and memantine use by patients in the Alzheimer Disease Neuroimaging Initiative. Arch Neurol (in press).
  21. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343–349
  22. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385–393
  23. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228–234
  24. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619–627
  25. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborgh B, De Deyn PP, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67:949–956
  26. Schmand B, Huizenga HM, Van Gool WA. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer’s disease. Psychol Med. 2009;29:1–11
  27. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512–519
  28. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med. 2005;24:329–339
  29. Schneider LS, Sano M. Current Alzheimer disease clinical trials: methods and placebo outcomes. Alzheimer Dement. 2009;5:388–397

 Study registration: ClinicalTrials.gov Identifier: NCT00106899.

PII: S1552-5260(10)02192-8

doi: 10.1016/j.jalz.2010.07.004

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 367-377 , September 2010

Article Tools

* Image Usage & Resolution